8375. Sarizotan
Nomenclature
CAS number: 351862-32-3
N-[[(2R)-3,4-Dihydro-2H-1-benzopyran-2-yl]methyl]-5-(4-fluorophenyl)-3-pyridinemethanamine; (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane; (R)-(-)-1-N-[5-(4-fluorophenyl)-3-pyridylmethyl]-N-2-chromanylmethylamine; EMD-77697. C22H21FN2O; mol wt 348.41.
C 75.84%, H 6.08%, F 5.45%, N 8.04%, O 4.59%.
Description and references
Dual serotonin 5-HT1A receptor agonist and dopamine D2 receptor antagonist. Prepn: H. B"ottcher et al., EP 707007; eidem, US 5767132 (1996, 1998 both to Merck Patent GmbH). PET receptor binding study: E. A. Rabiner et al., J. Psychopharmacol. 16, 195 (2002). Neurochemical profile: G. D. Bartoszyk et al., J. Neural Transm. 111, 113 (2004). Clinical evaluation in dyskinesia in Parkinson's disease: C. W. Olanow et al., Clin. Neuropharmacol. 27, 58 (2004); W. Bara-Jimenez et al., Mov. Disord. 20, 932 (2005).
Derivative
Dihydrochloride.Nomenclature
CAS number: 177976-12-4
EMD-128130. C22H21FN2O.2HCl; mol wt 421.34.
C 62.71%, H 5.50%, F 4.51%, N 6.65%, O 3.80%, Cl 16.83%.
Properties
mp 234-235°. [α]20 -65° (c = 1 in methanol).Therapeutic Category
Antidyskinetic.
Keywords
Antidyskinetic; Serotonin Receptor Agonist; Dopamine Receptor Antagonist